Lys399

Site Information
HGFIGCRkVTGtLDA SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 8104831

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 5 , 6 , 7 , 8 ) , mutation of modification site ( 3 )
Relevant cell line - cell type - tissue:	293 (epithelial) ( 3 ) , HEK293T (epithelial) ( 3 ) , HEp-2 (squamous) ( 1 ) , Jurkat (T lymphocyte) ( 1 ) , NCCIT (epithelial) ( 5 ) , PC3 (prostate cell) ( 6 , 7 , 8 ) , U2OS (bone cell) ( 2 )

Downstream Regulation
Effects of modification on biological processes:	cytoskeletal reorganization ( 3 )

References
1	Akimov V, et al. (2018) UbiSite approach for comprehensive mapping of lysine and N-terminal ubiquitination sites. Nat Struct Mol Biol 25, 631-640 29967540 Curated Info
2	Halim VA, et al. (2018) Doxorubicin-induced DNA Damage Causes Extensive Ubiquitination of Ribosomal Proteins Associated with a Decrease in Protein Translation. Mol Cell Proteomics 29438997 Curated Info
3	Lin S, et al. (2016) Monoubiquitination Inhibits the Actin Bundling Activity of Fascin. J Biol Chem 291, 27323-27333 27879315 Curated Info
4	Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610 27184836 Curated Info
5	Zhou J (2010) CST Curation Set: 9131; Year: 2010; Biosample/Treatment: cell line, NCCIT/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Curated Info
6	Possemato A (2009) CST Curation Set: 8585; Year: 2010; Biosample/Treatment: cell line, PC3/Geldanamycin; Disease: prostate cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Curated Info
7	Possemato A (2009) CST Curation Set: 8583; Year: 2010; Biosample/Treatment: cell line, PC3/AAG; Disease: prostate cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Curated Info
8	Possemato A (2009) CST Curation Set: 8584; Year: 2010; Biosample/Treatment: cell line, PC3/Geldanamycin; Disease: prostate cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Curated Info